Exiqon Launches New LNA™ Antisense Oligonucleotides for RNA Functional Analysis
News May 26, 2015
Exiqon A/S, a leading provider of flexible solutions for RNA analysis, has announced the launch of new Antisense LNA™ GapmeRs for targeted inactivation of RNA in functional studies.
Antisense LNA™ GapmerRs offer a powerful alternative to the existing siRNAs, and will be included in Exiqon’s cloud solution to be made available later in the year which integrates RNAseq, data analysis and custom products designed ‘to order’ based on sequencing data.
Exiqon’s Antisense LNA™ GapmeRs are designed using advanced proprietary bioinformatics algorithms which used in combination with the LNA™ technology secure antisense gapmers with excellent pharmacokinetic and pharmacodynamics properties including high stability and low toxicity for in vivo testing.
“We are thrilled to offer the new Antisense LNA™ GapmeR product that enables customers to functionally assess transcripts identified for instance by next generation sequencing no matter whether the transcript is located in the nucleus or in the cytoplasm” said Senior Vice President Sales & Marketing, Dr. Henrik M. Pfundheller and continues “We have also improved the web-interface of the custom design process and simplified the subsequent buying process”.
The Antisense LNA™ GapmeRs are high affinity antisense oligonucleotides used for functional analysis, allowing researches to study the gene function and downstream biological consequences of silencing a specific mRNA or long non-coding RNA (lncRNA) in cell-cultures or animal models.
Exiqon offers a range of compatible LNA™ enhanced products for mRNA and lncRNA research including products for qPCR and in situ hybridization analysis. Information about the Antisense LNA™ GapmeRs is available here:
Children who are genetically predisposed to overweight, due to common gene variants, can still lose weight by changing their diet and exercise habits. Around 750 children and adolescents with overweight or obesity undergoing lifestyle intervention participated in the study conducted by researchers from the University of Copenhagen and Holbæk Hospital.
6th World Congress on Human Genetics and Genetic Diseases
Apr 08 - Apr 09, 2019